ClinicalTrialsFinder
RecruitingNot ApplicableNCT06487546

Repletion of Ergothioneine in Patients With Kidney Failure

Sponsor

Stanford University

Enrollment

28 participants

Start Date

Apr 1, 2025

Study Type

INTERVENTIONAL

Conditions

ESRD

Summary

Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether supplementing a naturally occurring antioxidant compound called ergothioneine can improve health outcomes in people with kidney failure who are on dialysis, since this group has been found to have very low levels of this compound in their bodies. **You may be eligible if...** - You have kidney failure and are currently receiving dialysis (hemodialysis or peritoneal dialysis) **You may NOT be eligible if...** - You have had a blood transfusion within the last 90 days - You are already taking supplements that contain ergothioneine Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTErgothioneine

Participants will receive ergothioneine capsule daily for 12 weeks.

OTHERPlacebo

Participants will receive placebo capsule daily for 12 weeks.

Locations(1)

Veterans Affairs Palo Alto

Palo Alto, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06487546

Related Trials

Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis

NCT069136471 location

SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

NCT0600182728 locations

Adding Urea to the Final Dialysis Fluid

NCT063662301 location

SAfety of Regional Citrate Anticoagulation (SARCA Study)

NCT0533913910 locations

TESTING -ON Post-Trial ObservatioNal Cohort Study

NCT0543432558 locations